open access
Talimogene laherparepvec (T-VEC), review of a new therapy of cutaneous melanoma with genetically modified oncolytic virus
open access
Abstract
Talimogene laherparepvec (T-VEC) is the first (approved recently in the European Union) oncolytic immunotherapy which demonstrated therapeutic benefit for cutaneous melanoma in a phase III clinical trial. This resulted in a higher that previously obtainable response rate and median overall survival, particularly in untreated patients or those with stage IIIB, IIIC, or IVM1a disease. T-VEC was well tolerated and is currently studied in combined therapy with immunological checkpoints and in a neoadjuvant setting. In the review, current data on its efficacy and safety in melanoma therapy are discussed.
Abstract
Talimogene laherparepvec (T-VEC) is the first (approved recently in the European Union) oncolytic immunotherapy which demonstrated therapeutic benefit for cutaneous melanoma in a phase III clinical trial. This resulted in a higher that previously obtainable response rate and median overall survival, particularly in untreated patients or those with stage IIIB, IIIC, or IVM1a disease. T-VEC was well tolerated and is currently studied in combined therapy with immunological checkpoints and in a neoadjuvant setting. In the review, current data on its efficacy and safety in melanoma therapy are discussed.
Keywords
melanoma, oncolytis virus, talimogene laherparepvec
About this articleTitle
Talimogene laherparepvec (T-VEC), review of a new therapy of cutaneous melanoma with genetically modified oncolytic virus
Journal
Nowotwory. Journal of Oncology
Issue
Article type
Review paper
Pages
234-237
Published online
2016-07-12
Page views
1064
Article views/downloads
3432
DOI
Bibliographic record
Nowotwory. Journal of Oncology 2016;66(3):234-237.
Keywords
melanoma
oncolytis virus
talimogene laherparepvec
Authors
Piotr Rutkowski
Marcin Zdzienicki